Psychedelic News2023-08-08T14:20:44+02:00

News and Press Releases


Psyence Group Announces SEC Effectiveness Of F-4 For Proposed Business Combination Between Subsidiary And NASDAQ Listed Newcourt Acquisitions Corp

November 15, 2023|

Psyence Group Inc. (CSE:PSYG), a clinical-stage life science biotechnology company pioneering the use of nature-derived psilocybin in mental health and wellbeing (“Psyence”), and Newcourt Acquisition Corp  (Nasdaq: NCAC) (“Newcourt”), a special purpose acquisition company today announced that the registration statement on Form F-4 (the “Registration Statement”), filed by Psyence Biomedical Ltd. (“Pubco”) with the Securities and Exchange Commission (“SEC”) was declared effective by the SEC on November 13, 2023.

  • Psyence Production Expands Capability

Psyence Production Expands Capability

October 30, 2023|

Psyence recently designed a new laboratory at the facility in order to expand its extraction capabilities. The building of the laboratory has since commenced and is expected to be completed in Q4 2023. The expansion fits under the existing building footprint, and once completed, new state-of-the-art extraction equipment will be installed to enhance its current extraction capabilities. There are multiple potential benefits to on-site extraction including increased product shelf life, a more stabilized format for export, and reduced transport costs.

  • Corporate Updates - Psyence

Psyence Group Corporate Update

July 12, 2023|

Since Psyence’s corporate update issued in June 2022, the Company has made significant progress in its clinical trial programs and in upgrading its production facility and extraction capabilities. Psyence is executing on its strategy and is pleased to provide an update across the pillars of the business.

News and Press Releases

Psyence In The News

Psyence wins ISO certification from
British Standards Institute for
psilocybin production facility
Psyence Group’s functional mushroom brand
to be sold in South Africa’s
largest coffee retail chain
Psyence Group begins trading on the
OTCQB platform in New York
to satisfy investor demand
Psyence Group launches its functional
mushroom products under the
GOODMIND banner in South Africa
In this interview with Proactive Investors, Dr. Neil Maresky
talks about his appointment as
CEO of Psyence Group.
Psyence Group ‘delighted’ to reach
psilocybin product development
agreement with Jamaican government

Market For Psychedelic Drugs Expected to Reach $6.9 Billion By 2027

Psychedelic Finance chats to Psyence CEO Jody Aufrichtig

Psyence looking to be a major player
in psychedelics using their federally
licensed facilities
Jody Aufrichtig in conversation
with the CSE’s
Barrington Miller
Go to Top